Merck signs $356 million U.S. supply deal for its experimental COVID-19 treatment

(Reuters) -Merck & Co said on Wednesday it would supply 60,000-100,000 doses of its experimental COVID-19 treatment to the U.S. government for up to about $356 million.

Reuters December 24, 2020 00:06:02 IST
Merck signs $356 million U.S. supply deal for its experimental COVID-19 treatment

COVID-19 treatment" src="https://images.firstpost.com/wp-content/uploads/reuters/12-2020/24/2020-12-23T155515Z_1_LYNXMPEGBM13Q_RTROPTP_2_USA-MERCK.jpg" alt="Merck signs 356 million US supply deal for its experimental COVID19 treatment" width="300" height="225" />

(Reuters) -Merck & Co said on Wednesday it would supply 60,000-100,000 doses of its experimental COVID-19 treatment to the U.S. government for up to about $356 million.

The agreement will help support advanced development and large-scale manufacturing of the company's investigational therapeutic MK-7110 to treat hospitalized patients with severe or critical COVID-19 , the U.S. Department of Health and Human Services said.

The funding allows for development of MK-7110, including completing activities required to request emergency use authorization from the U.S. Food and Drug Administration, and for delivery of the doses by June 30, 2021.

Merck has built out its portfolio of COVID-19 treatments through a series of deals in recent months, including the acquisition of drugmaker Themis and a partnership with Ridgeback Biotherapeutics LP.

The company in November agreed to buy OncoImmune in a $425 million deal that gave it control of MK-7110, a promising first-in-class fusion protein and immune modulator. Immune modulators have the potential to minimize the damaging effects of an overactive immune response to COVID-19 .

Interim data from September showed that the therapy, which is administered as an injection, increased the likelihood of symptom improvement in serious COVID-19 cases and also reduced the risk of respiratory failure and death.

The doses will be made available to the American public at no cost, the agency said.

The United States has authorized two vaccine for emergency use this month and more than 600,000 Americans had received their first COVID-19 vaccine doses as of Monday, but the need for treatments for those hospitalized remain high.

Merck is also working on two potential vaccines that are still in early stages of development. It is also collaborating with Ridgeback in developing an antiviral treatment called molnupiravir.

The company's shares rose nearly 1% to $80 on Wednesday.

(Reporting by Ankur Banerjee in Bengaluru; Editing by Sriraj Kalluvila and Maju Samuel)

This story has not been edited by Firstpost staff and is generated by auto-feed.

Updated Date:

TAGS:

Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.

also read

Republicans face growing corporate backlash after Capitol assault
World

Republicans face growing corporate backlash after Capitol assault

By Andy Sullivan and David Shepardson WASHINGTON (Reuters) - Republicans in the U.S. Congress faced growing blowback on Monday from businesses that said they would cut off campaign contributions to those who voted last week to challenge President-elect Joe Biden's victory. The announcements by Dow Inc., AT&T Inc.

Guardians of Congo's gorillas unbowed as ambushed colleague is buried
World

Guardians of Congo's gorillas unbowed as ambushed colleague is buried

By Djaffar Al Katanty GOMA, Congo (Reuters) - A line of Congolese park rangers raised their guns in salute on Monday as the coffin bearing their colleague Burhani Abdou Surumwe, a 30-year-old father of four, was buried in the black volcanic soil of a Muslim cemetery outside Goma.

COVID-19 fuelling education's tech disruption, deepening digital divide
World

COVID-19 fuelling education's tech disruption, deepening digital divide

TORONTO/NEW YORK (Reuters) - The COVID-19 pandemic deepened inequities in accessing and benefiting from education but the future of learning could be a more equal one, participants told Reuters Next panels on Monday.